Replies to post #225202 on Biotech Values

[DewDiligence]

There are 4 levels of liver fibrosis F1 through F4. Yesterday FDA draft was for F4 (cirrhosis) and I actually agree with the [draft] FDA requirements.

Me too. The FDA’s draft guidance that phase-3 trials for this patient pool should show a clinical benefit (rather than a surrogate marker) relative to placebo seems reasonable.

[DewDiligence]

MDGL sells 1.38M* shares @$107.85—a 9% discount to yesterday’s close:

https://finance.yahoo.com/news/madrigal-pharmaceuticals-announces-pricing-secondary-045805721.html

*Assuming exercise of underwriter’s option.